Bristol-Myers Squibb's Daklinza Threatens Johnson & Johnson More Than Gilead Sciences

European approval of Bristol-Myers Squibb's Daklinza could derail sales of Johnson & Johnson's Olysio, but is unlikely to unseat Gilead's Sovaldi.

Aug 28, 2014 at 9:01AM

It isn't surprising to see that the European Commission has given Bristol-Myers Squibb (NYSE:BMY) the go-ahead for daclatasvir, Bristol's promising new hepatitis C treatment. Europe had already shown its willingness to support the use of daclatasvir, which will be sold under the brand name Daklinza, when it gave the OK for its compassionate use program last fall.

Now that Daklinza has the official go-ahead, sales should head markedly higher. If so, Daklinza poses a threat to Johnson & Johnson's (NYSE:JNJ) Olysio, a drug that has become increasingly prescribed as a companion drug alongside Gilead's (NASDAQ:GILD) top-selling hepatitis C drug Sovaldi.

Bristol Myers Hq

Source: Bristol-Myers Squibb Flickr.

Improving outcomes
Daklinza offers new hope for hepatitis C patients given its success as an adjunct treatment to Sovaldi. During mid-stage trials, combining Daklinza and Sovaldi cleared the virus in as many as 100% of patients, depending on the disease genotype, and succeeded in treating patients who had previously failed on Sovaldi alone. Overall, 99% of previously untreated genotype 1 patients achieved a functional cure after 12 weeks of treatment.

While those phase 2 trial results are impressive, Gilead opted against conducting a phase 3 study in order to focus on a combination therapy of its own two drugs: Sovaldi with ledipasvir.


Source: Gilead Sciences

Elbowing for scripts
The Holy Grail for hepatitis C drugmakers is an all-oral treatment regimen that casts aside side-affect laden prior-generation treatments ribavirin and peg-interferon. Although Sovaldi is an oral tablet that won approval last December, the medicine was only approved for use without interferon for genotype 2 and 3 hepatitis c. That meant that ribavirin still needed to be dosed alongside Sovaldi in all patients, and peg-interferon for genotypes 1 and 4. That requirement created a hurdle for doctors, given that many patients are either ineligible or unwilling to receive peg-interferon as part of their treatment.

In order to treat those patients, doctors have increasingly embraced prescribing Johnson & Johnson's Olysio, another oral hepatitis C drug that won regulatory approval in the fourth quarter, alongside Sovaldi. Despite Olysio underperforming Sovaldi versus prior generation therapies, in mid-stage trials the combo of Olysio and Sovaldi cleared hepatitis C in 93% of patients.

As a result, Olysio has been a far bigger success than many initially thought it would be. Johnson & Johnson notched $350 million in Olysio sales during the first quarter -- its first quarter on the market -- and an impressive $830 million in sales during the second quarter.

But even Johnson & Johnson recognizes that Olysio's success may be short-lived as new therapies like Daklinza make their way to market, enabling patients to move to an all-oral regimen without use of Olysio. Johnson & Johnson's CFO, Dominic Caruso, said on the company's second-quarter earnings conference call:

As you know we are anticipating that Olysio will face significant competition from new hepatitis C products later in the year, the full impact of which is difficult for us to predict at this point. And while we're not providing guidance for 2015, this will certainly pose a headwind next year.

Fool-worthy final thoughts
Heading into the end of the second quarter, Gilead reported that it was seeing signs that doctors were warehousing patients ahead of a wave of new treatments, including Daklinza and Gilead's own Sovaldi and ledipasvir combination. "We are seeing signs that physicians have begun delaying treatment for some patients also known as warehousing in anticipation of the approval of the single-tablet regimen of the differences across the derivatives," said Gilead's EVP Paul Carter on the company's second-quarter earnings conference call.

Gilead's second-generation Sovaldi treatment will likely allow it to continue to be the market-share leader in the multi-billion dollar market, but that doesn't mean there won't be room for Bristol-Myers' Daklinza. This is especially true in overseas markets like Japan and Europe, where Daklinza will have a longer, first-to-market advantage over Gilead's upcoming two-drug medicine. 

Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell owns shares of Gilead Sciences. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Gilead Sciences and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information